Povetacicept, a Vertex Pharmaceuticals immunology drug designed to block two targets, met the main goal of a Phase 3 clinical trial in the rare kidney disease immunoglobulin A nephropathy. The fusion protein came from Vertex’s acquisition of Alpine Immune Sciences, and analysts say the drug has best-in-class potential.
The post Vertex Pharma to Seek Speedy FDA Approval for Kidney Disease Drug From $4.9B Acquisition appeared first on MedCity News.
